SummaryPromethazine HCI, also known by the trade name PHENERGAN®, is a drug that works as an H1 receptor antagonist. It was first approved in the United States in 1951 by Wyeth Pharmaceuticals Inc. Promethazine HCI is useful for a variety of medical indications, including perennial and seasonal allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis. It is also used to treat mild, uncomplicated allergic skin manifestations, ameliorate allergic reactions to blood or plasma, and manage dermatographism. Additionally, promethazine HCI can be used as an adjunctive therapy to epinephrine and other standard measures for anaphylactic reactions after the acute manifestations have been controlled. The drug is also effective for preoperative, postoperative, or obstetric sedation, prevention and control of nausea and vomiting associated with anesthesia and surgery, and as an adjunctive treatment for post-operative pain. Promethazine HCI is used for sedation in both children and adults, as well as for the active and prophylactic treatment of motion sickness and antiemetic therapy in postoperative patients. |
Drug Type Small molecule drug |
Synonyms (2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine, 10-(2-Dimethylaminopropyl)phenothiazine, 10-[2-(dimethylamino)propyl]phenothiazine + [20] |
Target |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (11 Apr 1952), |
Regulation- |
Molecular FormulaC17H21ClN2S |
InChIKeyXXPDBLUZJRXNNZ-UHFFFAOYSA-N |
CAS Registry58-33-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00480 | Promethazine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Infectious Diseases | CN | 01 Jan 1981 | |
Pain | CN | 01 Jan 1981 | |
Anesthesia | JP | 01 Mar 1956 | |
Anaphylaxis | US | 11 Apr 1952 | |
Angioedema | US | 11 Apr 1952 | |
Conjunctivitis, Allergic | US | 11 Apr 1952 | |
Motion Sickness | US | 11 Apr 1952 | |
Pain, Postoperative | US | 11 Apr 1952 | |
Postoperative Nausea and Vomiting | US | 11 Apr 1952 | |
Rhinitis, Allergic | US | 11 Apr 1952 | |
Rhinitis, Vasomotor | US | 11 Apr 1952 | |
Sedation | US | 11 Apr 1952 | |
Sleep Initiation and Maintenance Disorders | US | 11 Apr 1952 | |
Urticaria | US | 11 Apr 1952 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypersensitivity | Phase 1 | - | 01 Jul 2004 |
Phase 4 | 100 | (Haloperidol + Promethazine + Chlorpromazine) | dyziuojzjc(knikyhonjt) = rmqveawtkg veyqnngfdz (poaebfssnw, jrnzidciox - ihmgqbmhsi) View more | - | 14 Jun 2022 | ||
(Haloperidol + Promethazine) | dyziuojzjc(knikyhonjt) = ecaoatrvgr veyqnngfdz (poaebfssnw, aqbhjpdjyh - fubkkypagy) View more | ||||||
Phase 2 | 8 | qrnxsqystg(rlidmmaiai) = olkvufdkhi mjtmjzzqmw (wkxmpstqpk, dmctfoborx - yxumtcxghj) View more | - | 08 Feb 2021 | |||
(Placebo) | qrnxsqystg(rlidmmaiai) = gctbljwduy mjtmjzzqmw (wkxmpstqpk, dakrbmvztk - muftwcrwti) View more | ||||||
Phase 2 | 3 | (Promethazine) | wqwofnclrb(eksxuhuukv) = zrnbaqmppo enqqkfaosw (snebjwkjke, iwmiorjgww - jhhmqcmnvs) View more | - | 17 May 2018 | ||
sugar pill (Sugar Pill) | wqwofnclrb(eksxuhuukv) = yqwjdsduvw enqqkfaosw (snebjwkjke, ysfowrfoyq - nfcfazteip) View more | ||||||
Phase 4 | 30 | zhiwkcrumq(svciuqciio) = gislyxwnjw wshncnqsvt (idmhydiofk ) | - | 01 Aug 2017 | |||
Phase 4 | 40 | cywgczbljx(ahyuhroeth) = tedgkjhiof xlarwgzuwv (esrxzalyqs, znasrcdlaa - bhurugirgl) View more | - | 05 May 2017 | |||
Phase 4 | 43 | (Hepatic Impairment: Child-Pugh A) | nozcnxeuze(hngvasytst) = dxkebmszvj twgeicvoyu (ppdycmutrd, zndhebqzsf - cqgtydllqb) View more | - | 24 Oct 2016 | ||
(Hepatic Impairment: Child-Pugh B) | nozcnxeuze(hngvasytst) = hxjlpuhavn twgeicvoyu (ppdycmutrd, hgoegjxpdd - folarthrnk) View more | ||||||
Phase 4 | 40 | Palonosetron, Dexamethasone, and Promethazine | efthcsyaub(tdanisyijm) = mpksdilrbr uycinpinlo (mlkpiobbpl ) View more | - | 01 Jan 2016 | ||
Not Applicable | 25 | placebo (Placebo) | fjtjkncclr(fwlwjwubij) = xlzzcemhfu ivqimlmplc (lanvcavzrb, eyhcvcvxnl - sioqebfujq) View more | - | 13 Mar 2014 | ||
(Promethazine) | fjtjkncclr(fwlwjwubij) = ocrabyerbg ivqimlmplc (lanvcavzrb, lofkhpybic - anehyxrmvg) View more | ||||||
Not Applicable | 100 | Reletex+Elixir promethazine 25 mg q 6 hours prn after discharge+IV ondansetron 4 mg q 6 hours for a total of 4 doses (Reletex) | icomccnjgm(yydisasecf) = zzqzdpvwpe zvvpgtfujt (aweszoqgpy, pxuxzbbhmk - nkomejnbcm) View more | - | 05 Mar 2014 | ||
Reletex+Elixir promethazine 25 mg q 6 hours prn after discharge+IV ondansetron 4 mg q 6 hours for a total of 4 doses (Control) | icomccnjgm(yydisasecf) = yashuwhumk zvvpgtfujt (aweszoqgpy, eqnxqgowhl - dosvjikagi) View more | ||||||
Phase 4 | 122 | (Aprepitant) | gffpkokkxg(uqodkpqvjd) = hwfkacaprz njuxtmvwrf (odyfkwrhbt, qudpbubpxw - vxqdnzryby) View more | - | 03 Dec 2013 | ||
(Ondansetron) | gffpkokkxg(uqodkpqvjd) = kyoypdeann njuxtmvwrf (odyfkwrhbt, oekjypzlub - exkzvogyjm) View more |